Human Derived Cell Substrate Characterization

Ensuring the safety, quality, and consistency of biopharmaceutical products relies heavily on robust cell line characterization. Compared to rodent systems like CHO, human-derived cell substrates present distinct requirements, including donor eligibility verification, human pathogen risk management, tissue traceability, and potential tumorigenicity or genomic integrity evaluations. Meeting these demands across the cell banking lifecycle—from Master Cell Banks (MCB) to Working Cell Banks (WCB) and End-of-Production (EOP) cells—requires a risk-based testing framework aligned with global regulatory guidelines such as ICH Q5D, ICH Q5A(R2), 21 CFR 1271, EMA, and WHO standards.

Minaris Advanced Testing combines comprehensive characterization services with full CGMP-compliant cell bank manufacturing. Covering cell expansion, harvest, cryopreservation, and testing for identity, purity, genetic stability, and viral safety, these integrated programs streamline regulatory data packages and accelerate program timelines. Download the full flyer to view detailed testing panels and assay specifications.